



## Recent Scientific Development of HIV Vaccine and HIV Prevention Strategies

Guest Editors:

**Dr. Jaykaran Charan**

Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India

**Dr. Nagesh Kolishetti**

Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA

Deadline for manuscript submissions:

**closed (15 November 2023)**

### Message from the Guest Editors

Dear Colleagues,

The past few years have witnessed many promising advances in HIV prevention strategies involving preexposure prophylaxis approaches. Despite the tremendous efforts to develop a successful human immunodeficiency virus (HIV) vaccine, the quest for a safe and effective HIV vaccine seems to be remarkably long. An effective vaccine is needed to stop the continuing spread of HIV worldwide. A number of unique characteristics of the biology of HIV infections make the creation of an HIV vaccine particularly challenging. Together with other HIV prevention approaches, preventive and therapeutic HIV vaccines will be invaluable tools in bringing the epidemic to an end.

This Special Issue is open to any subject area related to “HIV Vaccine and HIV Prevention Strategies”. We invite research employing quantitative and qualitative methods as well as contributions featuring under-researched populations.

Dr. Jaykaran Charan

*Guest Editor*

Please contact Ms. Ruby Liu/MDPI(ruby.liu@mdpi.com) , if you need a discount or waiver.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)